The trial assessed the efficacy, tolerability, and safety of the formulation in a titrated dose-escalation study of 13 subjects. Credit: Darren Baker / Shutterstock.

First Wave BioPharma has reported topline data from its Phase II SPAN clinical trial of an enteric microgranule delivery formulation of adrulipase capsule to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients.

The trial assessed the efficacy, tolerability, and safety of the formulation in a titrated dose-escalation study of 13 subjects.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Coefficient of fat absorption (CFA) is the primary efficacy endpoint while coefficient of nitrogen absorption (CNA), signs and symptoms of malabsorption and stool weight are secondary endpoints of the trial.

First Wave BioPharma president and CEO James Sapirstein said: “Preliminary data from the Phase II SPAN clinical trial indicate our enhanced microgranule delivery formulation of adrulipase was safe and well tolerated.

“We are in the process of analysing the dataset and anticipate having a topline review of the primary and secondary endpoints in the September timeframe.

See Also:

“We would like to thank the patients who volunteered to participate in the study and the investigators and their staff at our three participating clinical trial sites for ensuring that the trial was fully enrolled and completed on time.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

First Wave BioPharma plans to meet with the US Food and Drug Administration (FDA) to review the data.

In the meeting, the company and the FDA will discuss the parameters for initiating a Phase III trial that could fulfil the requirements for a Biologics License Application (BLA).

Adrulipase is a recombinant lipase enzyme and can break up fat molecules in the digestive tract of patients.